📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial. (2024)

First Author: Mateo J

Attributed to: Elucidating how Dysbiosis, Senescence and Inflammatory Storms Impact Prostate Carcinogenesis and Treatment Resistance to Transform Care. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.23.00339

PubMed Identifier: 37963304

Publication URI: http://europepmc.org/abstract/MED/37963304

Type: Journal Article/Review

Volume: 42

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 5

ISSN: 0732-183X